ストックスクリーナーアプリを入手
0.6376
5.12%
-0.0344
前日終値:
$0.672
開ける：
$0.6251
24時間の取引高:
15.99M
Relative Volume:
39.87
時価総額：
$21.29M
収益：
$454.00K
当期純損益:
$-21.72M
株価収益率:
-1.1947
EPS:
-0.5337
ネットキャッシュフロー:
$-25.74M
1週間 パフォーマンス:
-6.22%
1か月 パフォーマンス:
-3.20%
6か月 パフォーマンス:
+11.92%
1年 パフォーマンス:
-53.80%
1日の値動き範囲:
$0.6123
$0.6581
1週間の範囲:
$0.6123
$0.6845
52週間の値動き範囲:
$0.2805
$1.595
Vyne Therapeutics Inc Stock (VYNE) Company Profile
名前
Vyne Therapeutics Inc
セクター
電話
800-775-7936
住所
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6376 | 21.29M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-31 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-11-18 | 開始されました | BTIG Research | Buy |
| 2021-12-06 | 再開されました | H.C. Wainwright | Buy |
Vyne Therapeutics Inc (VYNE) 最新ニュース
VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience - Moomoo
Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend? - Kalkine Media
Vyne Therapeutics Declares Special Cash Divid - Moomoo
VYNE Announces Special Cash Dividend Ahead of Merger - GuruFocus
VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026 - marketscreener.com
VYNE Therapeutics declares $16.5M dividend ahead of merger - Investing.com
VYNE Therapeutics Announces $16.5M Special Cash Dividend Ahead of Merger with Yarrow Bioscience - Minichart
VYNE declares special dividend ahead of Yarrow merger - TipRanks
VYNE Therapeutics declares $16.5M special cash dividend tied to Yarrow merger - TradingView
VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience - Quiver Quantitative
VYNE Therapeutics (NASDAQ: VYNE) declares $0.38/share special dividend tied to merger - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
VYNE stock holds its ground. Focus turns to the company profile. - ad-hoc-news.de
VYNEVYNE Therapeutics Inc Forecast, Target Price - Finviz
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
VYNE Therapeutics (VYNE) CSO reports 2,370-share tax withholding on RSU vesting - Stock Titan
VYNE Therapeutics (VYNE) CLO has shares withheld to cover RSU taxes - Stock Titan
VYNE (VYNE) CEO Domzalski has 12,214 shares withheld for RSU taxes - Stock Titan
Price to book forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Enterprise value to EBIT forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to earnings forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to sales forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Enterprise value to EBITDA forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE) - TradingView
VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE) - TradingView
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
VYNE Therapeutics StockSunday background on a micro-cap dermatology player - AD HOC NEWS
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[EFFECT] VYNE Therapeutics Inc. SEC Filing - Stock Titan
VYNE (VYNE) merger with Yarrow: $100M financing, 35.8441 exchange ratio - Stock Titan
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
VYNE Q1 2026 Earnings: EPS Beat Estimate, No Revenue ReportedFinancial Summary - newsline.com
VYNE Therapeutics (VYNE) Edges Higher in Quiet Trading, Testing Key Resistance at $0.69New Listing Stocks - newsline.com
VYNE Therapeutics (VYNE) Consolidates Near Support After Slight PullbackMACD Signal Stocks - newsline.com
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) Posts Modest Gain, Holds Above Key SupportMotive Wave - newsline.com
VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65Standard Deviation - thelegaladvocate.com
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
VYNE Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost DisciplineEarnings Preview - dars.gov.et
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vyne Therapeutics Inc (VYNE) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):